医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

AGC Earns The Skin Cancer Foundation’s Seal of Recommendation for Automotive Windows in All Directions for the First Time in the World

2015年12月21日 PM11:00
このエントリーをはてなブックマークに追加


 

TOKYO

AGC, a world-leading manufacturer of glass, chemicals and high-tech materials, announced that it has earned The Skin Cancer Foundation’s Seal of Recommendation, an international symbol of safe and effective sun protection, for UV Verre Premium Privashield™. This newly released product is a dark-tinted privacy glass for automotive rear doors and rear windows that cuts ultraviolet (UV) rays by about 99%*1. In combination with the UV-cut glass for front windshields and front door windows for which the company has already earned the Seal of Recommendation, AGC has become the first company in the world*2 to offer automotive windows for all directions (i.e. front, side and rear) bearing The Skin Cancer Foundation’s Seal of Recommendation.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20151221005333/en/

The Skin Cancer Foundation is the only international organization solely devoted to the prevention, early detection and treatment of the world’s most common cancer. For protecting people from UV rays which are said to be one of the causes of skin cancer, AGC launched sales of its UV Verre Premium™ series in 2010, the world’s first*3 front door glass with an approximately 99% UV reduction performance. In 2013, AGC earned The Skin Cancer Foundation’s Seal of Recommendation for the UV Verre Premium™ series and LAMISAFE™ front windshield, and these products are being used as anti-UV measures for driver and front passenger seats in about 50 automobile models*4 across the world.

In November, 2015, AGC brought these products’ highly praised functionality to the rear door and rear window glass with the launch of UV Verre Premium Privashield™, which now has also earned The Skin Cancer Foundation’s Seal of Recommendation. With this achievement, AGC is able to offer the world’s first*2 automobile interior spaces enclosed in all directions by automotive glass bearing The Skin Cancer Foundation’s Seal of Recommendation.

Under its management policy of AGC plus, AGC is committed to contribute to the safety, security and comfort of the world by developing and providing products that bring comfort to people’s lives.

*1. Values measured by AGC under the ISO9050 standard.
*2, 4. As of December 2015, according to AGC survey.
*3. As of December 2010, according to AGC survey.

Reference

1. The Skin Cancer Foundation’s Seal of Recommendation
The Skin Cancer Foundation is the only international organization solely devoted to the prevention, early detection and treatment of the world’s most common cancer. Its Seal of Recommendation is granted to sun protection products that have been reviewed by and meet the specific criteria of an independent Photobiology Committee. The Seal is a symbol of safe and effective sun protection that is recognized by consumers worldwide. Sun protective products with the Seal include sunscreens, sunglasses, auto and residential window film and glass, awnings/umbrellas, clothing and laundry products.

Visit http://www.skincancer.org/ for further information on The Skin Cancer Foundation.

2. 99% UV-cut glass in All Directions
The combination of the following glass products enables approx. 99% UV reduction in all directions (i.e. front, side and rear), protecting the driver and passengers from UV rays.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151221005333/en/

CONTACT

Inquiries regarding this press release:
Asahi Glass CO., LTD
General
Manager: Junichi Kobayashi
Rep: Takuya Miyagawa
+81-3-3218-5603
Corporate
Communications & Investor Relations
info-pr@agc.com
or
AGC
Automotive Americas
Marketing Manager: Jacqueline Fette
+1-734-793-4322
Jacqueline.fette@us.agc.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 苏尔寿:IDS 2017出现仿冒品和专利侵权者——苏尔寿混合技术有限公司将继续行使其权利
  • New CDISC Standard Empowers Smarter Research for Diabetic Kidney Disease
  • Dr. Reddy’s and CHD Bioscience Announce Global License and Commercialization Agreement for Phase III Clinical Trial Candidate for Mitigation of Surgical Site Infections
  • Dr. Reddy’s Q1 FY18 Financial Results
  • Cogstate Receives Positive FDA Notification Regarding Medical Device Regulatory Submission